Abstracts sitivity and construct validity are warranted, and could be conducted as part of ongoing clinical trials.
University of Michigan/ Pfizer, Ann Arbor, MI, USA; 2 Pfizer, Inc, Ann Arbor, MI, USA OBJECTIVES: The purpose of this study is to estimate the number of physician visits for a primary complaint of insomnia and characterize patients with a primary complaint of insomnia, diagnosis of insomnia and patients utilizing sleep medications. METHODS: Data was obtained from the 2001 version of the National Ambulatory Medical Care Survey. Descriptive analyses were utilized to examine individuals with a primary complaint of insomnia and/or diagnosed with insomnia. Patient level weights were utilized to derive national population estimates from a representative sample. RESULTS: In 2001, there were 1.6 million patient visits for a primary complaint of insomnia. More females than males (87% vs. 17%), and more Caucasians than other races (64% vs. 36%) reported insomnia as their primary complaint. While only 22% of patients complaining of insomnia were diagnosed with a sleep disorder, a significant number (79%) were prescribed a medication, including Ambien or Sonata (26%) and Benadryl (10%). During the same year, 4.8 million patients were diagnosed with a sleep disorder. Patients were diagnosed by generalist (67%), Psychiatrist (3%) and other specialist (43%). Yet, only 9% of patients diagnosed with a sleep disorder had a primary complaint of insomnia upon visiting their physician. Medications were utilized by 76% of these patients including Ambien or Sonata (15%) and Benadryl (3%). Only 15% of patients using Ambien or Sonata and only 4% of patients taking Benadryl were diagnosed with a sleep disorder. CON-CLUSIONS: This work describes the characteristics of patients with a primary complaint of insomnia and their resultant diagnosis and pharmaceutical treatment. Additionally, we look at patients diagnosed with insomnia and describe the most common patient reported reason for their visit and their pharmaceutical treatment. To investigate the sensitivity of cost-effectiveness (CE) estimates of drug treatment that delays disability progression in Multiple Sclerosis (MS) to international differences in the underlying natural history of the disease. METHODS: Simulation model Multiple Sclerosis PharmacoEvaluation Tool (MS-PEET) was developed to estimate the CE of drug treatment that delays disability progression in Multiple Sclerosis. MS-PEET was initially populated with Swedish data on the natural history of disability progression, measured by the cumulative probability of patients reaching three disease-specific severity endpoints (EDSS 3, 6, 10) . Treatment effectiveness is modeled as a reduction in the probability of EDSS progression. This analysis compares CE estimates based on Nova Scotia natural history data with estimates based on Swedish data, holding all other variables constant. Nova Scotia natural history data is from the Dalhousie Multiple Sclerosis Research Unit (DMSRU). The DMSRU has up to 25 years of clinical follow-up for 2368 patients. RESULTS: Preliminary analysis of untreated patients in DMSRU data shows a less severe natural history course in Nova Scotia relative to Sweden. The reported cumulative probability of progressing to severe disability (EDSS ≥ 6) within 10 years of MS-onset is almost 60 percent less in Nova Scotia than in Sweden. CE estimates based on Nova Scotia natural history data are roughly 150 percent higher than estimates based on Swedish data. CONCLUSION: A less severe MS natural history course limits potential gains in terms of disability years avoided with treatment. Consequently estimates of cost-effectiveness are likely to be sensitive to differences in the underlying natural history. MS-
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